Joint Development Agreement with OCUMENSION for Retinal Diseases and MSC2
First written in FY2020. 2 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「In March 2020, the Company Group entered into a business partnership agreement with Ocumension (Hong Kong) Limited for the research, development and commercialization of regenerative cell therapy products in ophthalmology, covering SB623 and MSC2.」
The framework for advancing the research, development and commercialization of SB623 for retinal disease indications and MSC2 in Greater China under the partnership with Ocumension has been reconfirmed. - FY2022AdvancedAnnual report
「The company has now begun nonclinical studies under a co-development framework with Ocumension (Hong Kong) Limited and is working to obtain the data required to initiate clinical trials.」
The joint development of retinal disease treatments with Ocumension progressed from the previous partnership and planned joint development stage to the start of preclinical studies and the collection of data for clinical trials. - FY2021-Q1RestatedAnnual report
「As part of expanding the indications, we entered into a business partnership with China’s OCUMENSION (HONG KONG) LIMITED in March 2020. Going forward, we plan to jointly develop SB623 and MSC2 cell therapies in Greater China, including mainland China, Hong Kong, Macau, and Taiwan, for retinitis pigmentosa, age-related macular degeneration (dry type), and other conditions.」
The policy of jointly developing SB623 for retinal disease indications and the MSC2 cell therapy product in Greater China under the business partnership with OCUMENSION has been reconfirmed. - FY2020First statedAnnual report
「In March 2020, the Company entered into an agreement with OCUMENSION (HONG KONG) LIMITED for the joint development in Greater China, including mainland China, Hong Kong, Macau and Taiwan, of treatments indicated for retinitis pigmentosa, dry age-related macular degeneration and other retinal diseases.」
In March 2020, the Company entered into an agreement with OCUMENSION concerning the research, development and commercialization in Greater China of SB623 for retinal diseases and MSC2 for optic neuritis. Development costs are to be shared, with milestone payments expected during development and sales-based royalties expected after launch.